Pain Manag. 2025 Aug 6:1-8. doi: 10.1080/17581869.2025.2543232. Online ahead of print.
ABSTRACT
BACKGROUND: The primary objective of this randomized, double-blind, parallel-group trial is to evaluate the efficacy and safety of intrathecal hyperbaric bupivacaine in conjunction with either fentanyl or dexmedetomidine in mitigating visceral pain during cesarean delivery.
METHOD: One hundred and sixteen parturients, classified as ASA II-III and scheduled for elective cesarean section, will be randomized 1:1 into two groups: Group BF will receive 10 mg hyperbaric bupivacaine in combination with 10 µg fentanyl. In contrast, Group BD will receive 10 mg hyperbaric bupivacaine in combination with 5 µg dexmedetomidine. The primary outcome is the frequency and intensity of visceral pain, assessed using an 11-point numerical rating scale at pivotal intraoperative stages. Secondary outcomes include hemodynamic stability, neonatal Apgar scores, shivering frequency, and the incidence of adverse effects.
CONCLUSION: The primary hypothesis of this study is that dexmedetomidine may offer superior visceral pain control with a reduced incidence of adverse effects.
MAKING CESAREAN BIRTHS MORE COMFORTABLE: Comparing Two Pain Relief Medicines Used in A cesarean birth (C-section) is often done under spinal anesthesia, which numbs the lower body, while the mother stays awake. While this works well for most women, some still feel uncomfortable or experience painful sensations in their belly during surgery, especially when the uterus is touched or moved. This kind of deep belly pain is called visceral pain.
CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT06367660; Nepal Health Research Council (NHRC) Protocol ID: 98-2024.
PMID:40765391 | DOI:10.1080/17581869.2025.2543232
